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Purpose: DNA methylation is an important epigenetic mechanism of gene regulation 
and plays essential roles in tumor initiation and progression. Differences in methyl-
ation patterns between neoplastic and normal cells can be used to detect the presence 
of cancer. The aim of the present study was to evaluate the usefulness of gluta-
thione-S-transferase-Pi (GSTP1) hypermethylation in discriminating between normal 
and prostate cancer (PCa) cells and in predicting tumor characteristics by use of quanti-
tative pyrosequencing analysis.
Materials and Methods: A total of 100 human prostate tissues obtained from our in-
stitute were used in this study: 45 for benign prostatic hyperplasia (BPH) and 55 for 
PCa. The methylation level of GSTP1 was examined by a quantitative pyrosequencing 
analysis. The associations between GSTP1 methylation level and clinico-pathological 
parameter were also compared.  
Results: The level of GSTP1 methylation was significantly higher in PCa samples than 
in BPH samples (56.7±32.7% vs. 1.6±2.2%, p＜0.001). The sensitivity and specificity 
of GSTP1 methylation status in discriminating between PCa and BPH reached 85.5% 
and 100%, respectively. Even after stratification by stage, Gleason score, and pros-
tate-specific antigen (PSA) level, similar results were obtained. A positive correlation 
between GSTP1 methylation level and serum PSA level was observed (r=0.303, 
p=0.002). There were no associations between GSTP1 methylation level and age, 
Gleason score, and staging. 
Conclusions: Our study demonstrates that GSTP1 methylation is associated with the 
presence of PCa and PSA levels. This methylation marker is a potentially useful in-
dicator for the detection and monitoring of PCa.
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INTRODUCTION
Prostate cancer (PCa) remains a major medical health is-
sue representing one of the frequent cancers among men. 
The discovery and widespread utilization of serum pros-
tate-specific antigen (PSA) monitoring for early detection 
has greatly changed the way PCa is diagnosed and has re-
sulted in the downstaging of the disease [1-5]. Active PCa 
screening with the use of serum PSA level monitoring and 
digital rectal examination is now widely prevalent in many 
countries [1,2]. The gold standard for PCa diagnosis is his-
topathologically reviewed prostatic biopsy cores. This tech-
nique, although generally effective, is subject to sampling 
errors and a significant false-negative rate [1,2]. Thus, the 
development of new tumor markers with better sensitivity 
and specificity to detect early cancer remains vitally 
important.
DNA hypermethylation-induced silencing of tumor sup-
pressor and DNA repair genes is a frequent phenomenon 
affecting the hallmarks of cancer [6-9]. The genes under-Korean J Urol 2012;53:200-205
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going methylation during the early phases of tumori-
genesis could potentially be used as markers for identifying 
individuals at increased risk of developing malignancy or 
for aiding in the diagnosis of early malignancy, whereas 
those genes undergoing methylation during the pro-
gression of malignancy could potentially be used as prog-
nostic markers [6-9]. These hypermethylation markers are 
promising tools for detecting cancer cells in tissue and body 
fluids, and various approaches for the detection of aberrant 
DNA methylation regions have been developed in recent 
years [7-10]. Most previous studies used methylation-spe-
cific polymerase chain reaction (MSP) or quantitative 
methylation-specific polymerase chain reaction (QMSP) to 
assess methylation status and often artificially catego-
rized the data into simplistic hypermethylated or hypo-
methylated categories [7-9]. Despite common use, these 
methods have known disadvantages such as false-positive 
and false-negative results as well as the use of relative com-
parisons instead of absolute quantification [11,12]. To 
quantify DNA methylation, pyrosequencing (PSQ) is one 
of the most accurate techniques available [7,11,12].
CpG island methylation of glutathione-S-transferase-Pi 
(GSTP1) has been detected in several cancer types, includ-
ing breast and hepatocellular cancer, but only in PCa is this 
abnormality consistently detected with a high specificity 
and rarely found in patients without disease [13-18]. The 
aim of the present study was to evaluate the relevance of 
GSTP1 methylation status in discriminating between be-
nign prostatic hyperplasia (BPH) and PCa as well as its as-
sociation with clinico-pathological parameters by use of a 
quantitative PSQ analysis. 
MATERIALS AND METHODS
1. Human tissue samples
A total of 100 human prostate tissue samples obtained from 
our institute were used in this study: 45 for BPH and 55 
for PCa. Patients with PCa underwent radical prostatec-
tomy or palliative transurethral resection (TUR), and pa-
tients with BPH underwent TUR. All tissues were mac-
ro-dissected within 15 minutes of surgical resection. Each 
prostate specimen was confirmed by pathological analysis 
of fresh-frozen sections, and the rest of the tissue was frozen 
in liquid nitrogen and stored at -80
oC until use. The collec-
tion and analysis of all samples were approved by the local 
institutional review board, and informed consent was ob-
tained from each subject. 
2. DNA extraction and pyrosequencing analysis
Genomic DNA was extracted by standard methods by use 
of the Wizard Genomic DNA Purification System (Promega, 
Madison, WI, USA). Bisulfite modification of genomic DNA 
(500 ng) was performed with an EZ DNA methylation kit 
(Zymo Research, Orange, CA, USA) according to the manu-
facturer’s recommendation. GSTP1 methylation was ex-
amined by PSQ. Polymerase chain reaction (PCR) and se-
quencing primers were designed with PyroMark Assay de-
sign ver. 2.0.1.15 (Qiagen, Valencia, CA, USA). The PSQ 
assay was designed to evaluate the methylation status of 
seven CpG sites. The total length of the amplicon was 199 
bp and the following primers were used: forward 
5’-GAGTTAGAGGGATTTTTTAGAAGAG-3’ and reverse 
biotinylated 5’-CAATTAACCCCATACTAAAAACTCT-3’. 
The PCR thermal cycling conditions were as follows: dena-
turation at 94
oC for 5 minutes; 45 cycles of 95
oC for 30 sec-
onds, 52
oC for 30 seconds, and 72
oC for 30 seconds; and a 
final extension at 72
oC for 5 minutes. PCR reactions were 
carried out with 1 μl of bisulfite-converted genomic DNA 
for all prostate tissues. A biotin-labeled primer (reverse 
primer) was used to purify PCR product by use of streptavi-
din-coated Sepharose beads (GE Healthcare, Buckingha-
mshire, UK). PCR product was bound to Sepharose beads, 
purified, washed, denatured by using a 0.2 mol/l NaOH sol-
ution, and washed again. Then 0.3 μmol/l pyrosequencing 
primer (5’-GGGAGGGATTATTTTTATAAGG-3’) was an-
nealed to the purified single-stranded PCR product and the 
pyrosequencing was performed on a PyroMark Q96 ID 
(Qiagen) according to the manufacturer’s instructions. To 
provide the internal control for total bisulfite conversion, 
a non-CG cytosine in the region for PSQ was included where 
possible. Target CpG sites were evaluated by use of instru-
ment software (PSQ96MA 2.1, Qiagen) that converts the 
pyrograms to numerical values for peak heights and calcu-
lates the proportion of methylation at each base as a C/T 
ratio. Data analysis was performed by using PyroMark 
Q96 ID ver. 1.0 (Qiagen).
3. Statistical analysis
We compared the quantitative GSTP1 methylation level 
and its association with clinico-pathological character-
istics in BPH and PCa patients. The methylation level of 
each sample was expressed as the mean value (the sum of 
the methylation level of each CpG site, n=7). The differ-
ences in continuous variables between the groups were as-
sessed by use of two-sample t-tests. Categorical variables 
were compared by using the chi-square test. The optimal 
sensitivity and specificity with DNA methylation of GSTP1 
for discriminating between PCa and BPH was determined 
by receiver operator characteristic (ROC) curve analysis by 
use of MedCalc software (MedCalc Software, Mariakerke, 
Belgium). The area under the ROC curve and the methyl-
ation threshold yielding the optimal sensitivity and specif-
icity for the prediction of PCa were calculated. By use of the 
same thresholds, the sensitivity, specificity, positive pre-
dictive value, and negative predictive value were also 
calculated. Pearson’s correlation was used to evaluate the 
relation between the GSTP1 methylation level and clin-
ico-pathological parameters. Tests for trend were per-
formed by analysis of variance trend analyses by using pol-
ynomial contrasts. For statistical purposes, PCa patients 
were divided into subgroups according to the following clin-
ico-pathological parameters: 1) Gleason score (GS≤6, 
GS=7, and GS≥8), 2) stage (T2, T3, and T4), and 3) PSA 
level at diagnosis (PSA＜10, 10 to 20, and ≥20 ng/ml). Korean J Urol 2012;53:200-205
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TABLE 1. Baseline characteristics of the patients included in the 
study
BPH (n=45) PCa (n=55) p-value
Age 
    Range
PSA (ng/ml) 
Total prostate 
  volume (ml)
Source of tissue (%)
TUR
Prostatectomy
68.6±8.2
  4.9±5.7
  36.7±17.3
45 (100)
70.1±6.8
  149.1±325.0
  39.5±17.1
33 (60.0)
22 (40.0)
0.333
0.002
0.430
Values are presented as mean±standard deviation or number (%).
BPH, benign prostatic hyperplasia; PCa, prostate cancer; PSA, 
prostate-specific antigen; TUR, transurethral resection.
FIG. 1. An example of GSTP1 pyrograms in benign prostatic hyperplasia (A) and prostate cancer (B) patients. Pyrogram includes 7 
CpG sites and methylation rates. The methylation level of GSTP1 is expressed as a mean. 
Statistical analysis was performed by using SPSS ver. 12.0 
(SPSS Inc., Chicago, IL, USA), and a p-value of ＜0.05 was 
considered statistically significant.  
RESULTS
1. Baseline characteristics
The baseline characteristics of the patients are presented 
in Table 1. The mean age and total prostate volume were 
not significantly different between the BPH and PCa 
groups. PCa patients had elevated levels of PSA compared 
with BPH patients.  
2. Methylation level in prostate tissues
Fig. 1 shows an example of the pyrograms in BPH and PCa 
patients. The methylation level of GSTP1 was significantly 
higher in PCa samples than in BPH samples (56.7±32.7% 
vs. 1.6±2.2%, p＜0.001) (Fig. 2A). In the ROC analysis, the 
area under the curve of the GSTP1 methylation level for 
the prediction of PCa reached 0.908 (95% confidence inter-
val [CI], 0.834 to 0.957) (Fig. 2B). For well-balanced sensi-
tivity and specificity, the GSTP1 methylation value corre-
sponded to a cutoff of 13.3%. That cutoff showed 85.5% sen-
sitivity (95% CI, 73.3 to 93.5%), 100% specificity (95% CI, 
92.1 to 100%), 100% positive predictive value (95% CI, 92.5 
to 100%), and 84.9% negative predictive value (95% CI, 72.3 
to 93.3%), respectively. Patients were divided into hyper-
methylated and unmethylated groups by use of a cutoff 
level. As presented in Table 2, GSTP1 was methylated in 
85.5% (47/55) and 0% (0/45) of PCa and BPH samples, 
respectively. Similar results were obtained even after 
stratification by PSA level, stage, and Gleason score.
3. Association between methylation level and clinico- 
pathological parameters in PCa patients
To evaluate the relation between GSTP1 methylation level 
and clinico-pathological parameters, we performed a corre-
lation analysis. No correlation was found between GSTP1 
methylation level and age (r=0.077, p=0.445) or Gleason 
score (r=-0.025, p=0.859). In contrast, we found a positive 
correlation between GSTP1 methylation level and serum 
PSA level (r=0.303, p=0.002). We also compared the GSTP1 
methylation levels on the basis of the corresponding clin-
ico-pathological parameters (Gleason score [GS≤6, GS=7, 
and GS≥8], stage [T2, T3, T4], and PSA level [PSA＜10, 
10 to 20, ≥10 ng/ml]). GSTP1 methylation levels increased 
similarly with increasing PSA level (p trend＜0.001) (Fig. 
3), whereas no trend was found between GSTP1 methyl-
ation level and Gleason score or stage (p trend＞0.05, re-
spectively). 
DISCUSSION
Our results demonstrated that the methylation level of 
GSTP1 was significantly higher in PCa patients than in Korean J Urol 2012;53:200-205
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FIG. 2. (A) GSTP1 methylation level in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients. Differences (p-value) 
between BPH and PCa patients were obtained by two-sample t-test. The y axis indicates the absolute methylation expression level 
of GSTP1. (B) Receiver operator characteristic (ROC) curve analysis of GSTP1 methylation for PCa prediction. 
TABLE 2. Frequency of GSTP1 methylation in human prostate 
tissues
BPH (n=45) PCa (n=55)
Methylation rate
a 
PSA level (ng/ml)
    ＜10  
    10–20
    ≥20
T staging 
    T2
    T3
    T4
Gleason score
    ≤6
    7
    ≥8
  0 (0/45)
  0 (0/40)
0 (0/3)
0 (0/2)
-
-
-
-
-
-
    85.5 (47/55)
62.5 (5/8)
66.7 (4/6)
    92.7 (38/41)
    81.5 (22/27)
    83.3 (15/18)
    100 (10/10)
100 (4/4)
   84.2 (16/19)
   84.4 (27/32)
BPH, benign prostatic hyperplasia; PCa, prostate cancer; PSA, 
prostate-specific antigen.
a: Methylation rate is expressed as percentage (no. of methylated 
samples/total number of samples). 
FIG. 3. GSTP1 methylation level according the prostate-specific 
antigen (PSA) level. Differences (p-value) among groups were 
calculated by analysis of variance trend analyses. The y axis 
indicates the absolute methylation expression level of GSTP1.
BPH patients. Moreover, GSTP1 hypermethylation was 
not only associated with an increased incidence of PCa, but 
was positively related to increases in the PSA level. In con-
trast, no significant relationships between GSTP1 methyl-
ation and age, stage, or Gleason score were established. 
Methylation of a promoter region has been shown to be 
associated with suppression of gene transcription, and 
hence gene expression. CpG island methylation is thought 
to influence transcription by allowing the attachment of 
methyl-binding domain proteins, which indirectly block 
the binding of transcription factors [7-9,14]. Abnormal 
DNA methylation patterns are associated with many hu-
man tumor types, and differences in methylation patterns 
have also emerged as markers for cancer risk assessment, 
cancer diagnosis, and therapy monitoring in several differ-
ent types of cancer [7-9]. Moreover, DNA methylation for 
cancer detection is quite powerful owing to the inherent 
stability of DNA compared with RNA or protein [8]. To date, 
aberrant methylation of CpG island-containing promoters 
of numerous hypermethylated loci including GSTP1 has 
been identified in PCa [7,10,14]. However, even in the same 
gene, the inconsistency of methylation levels reported in 
PCa could be the result of several factors, not the least of 
which is the different sample types used [7,13,14]. The var-
iation could also be a result of different analytical methods 
and how they are applied, including the pretreatment of the 
DNA, the PCR conditions, and the PCR method. Recently, 
with technical developments, various methods have be-
come available for the detection of the methylation status 
of certain genes in clinical samples [7,8]. Conventional 
MSP has been shown to have limited usefulness for specific 
cancer detection because benign lesions can be weakly pos-Korean J Urol 2012;53:200-205
204 Yoon et al
itive and cannot be distinguished from cancer cases. 
Moreover, the results of MSP at a particular DNA region 
are simply reported as methylated or unmethylated, which 
may be also subjective, thus not allowing quantitation or 
identification of partial methylation. For improvement of 
sensitivity and quantitation, various techniques, such as 
nested two-stage PCR and QMSP, have been developed. 
However, these methods also have known drawbacks, such 
as false-positive and false-negative results, as well as the 
use of relative comparisons instead of absolute quantifica-
tion [7,8,11,12]. In these regards, PSQ might be a best alter-
native tool, because it provides absolute quantitative in-
formation on bases at each interrogated CG site. Additio-
nally, the assay design readily allows the interrogation of 
different parts of the gene(s) of interest as well as the in-
clusion of internal controls to address inaccuracies result-
ing from incomplete bisulfite conversion [7,11,12]. In the 
present study, we utilized PSQ to evaluate methylation 
status, and provided an optimal cutoff level to discriminate 
between PCa and normal controls. Our provided cutoff lev-
el was relatively low; thus, it might be misleading with the 
use of other techniques [7,11,12]. One of the major advan-
tages of PSQ is the ability to quantitatively compare sam-
ples and to more accurately segregate varied pathologic co-
variates on the basis of methylation levels. If we did not use 
PSQ, we would not have found the significant correlation 
between GSTP1 methylation and PSA level.
GSTP1 is involved in the metabolism, detoxification, and 
elimination of potentially genotoxic foreign compounds, 
and thus acts to protect cells from DNA damage and cancer 
initiation. Suppression of GSTP1 activity can result in en-
hanced susceptibility to DNA damage and increased can-
cer incidence [13,14]. Many works have been reported on 
the development of GSTP1 methylation as a biomarker 
that could be used to detect PCa [13-18]. Most studies have 
reported a consistent link between GSTP1 methylation 
and PCa. Although the strength of the association has var-
ied, in tissue samples taken by biopsy or during surgery, 
GSTP1 methylation has been detected in at least 70% of 
cases and is only rarely present in benign prostate tissue 
[13-18]. As previously mentioned, various reasons exist for 
this inconsistency in GSTP1 methylation levels, including 
the detection methods and different tissue types used. Our 
findings are consistent with these previous results and in-
dicate that GSTP1 hypermethylation is a reliable indicator 
for the prediction of PCa.
Although histologically confirmed prostate tissues were 
used, the possibility of unrevealed PCa in BPH patients 
and a small fraction of undetected methylated DNA mole-
cules might have affected our results for sensitivity and 
specificity. Nonetheless, in terms of methylation frequen-
cy, our results are promising. The sensitivity and specific-
ity of GSTP1 methylation in distinguishing PCa and be-
nign tissue reached 85.5% and 100%, respectively. More-
over, the frequency of GSTP1 methylation in PCa was in-
dependent of serum PSA level, Gleason score, and stage. 
Clearly, biopsy has no potential as a routine screening test 
because of its highly invasive nature. Although these find-
ings are promising, multicenter, large-scale clinical vali-
dation studies with primary human cancer tissue and body 
fluids are currently underway at our institute to confirm 
GSTP1 as a diagnostic PCa methylation marker. These 
kinds of efforts will improve our understanding of the role 
of GSTP1 methylation in tumorigenesis and its clinical 
relevance. 
CONCLUSIONS
The results of our study show that GSTP1 methylation is 
associated with the presence of PCa and PSA levels. This 
methylation marker represents a potentially useful in-
dicator for the detection and monitoring of PCa.
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